These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35245821)
1. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy. Okcu O; Öztürk SD; Öztürk Ç; Şen B; Yasin Aİ; Bedir R Ann Diagn Pathol; 2022 Jun; 58():151930. PubMed ID: 35245821 [TBL] [Abstract][Full Text] [Related]
2. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers. Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866 [TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251 [TBL] [Abstract][Full Text] [Related]
5. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543 [TBL] [Abstract][Full Text] [Related]
8. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers. Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948 [TBL] [Abstract][Full Text] [Related]
9. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942 [TBL] [Abstract][Full Text] [Related]
10. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis. Yokotani T; Ikeda N; Hirao T; Tanaka Y; Morita K; Fujii T; Ohbayashi C; Nakamura T; Kobayashi T; Sho M Surg Today; 2021 Apr; 51(4):595-604. PubMed ID: 33052489 [TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559 [TBL] [Abstract][Full Text] [Related]
13. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers. Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Jang N; Kwon HJ; Park MH; Kang SH; Bae YK Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719 [TBL] [Abstract][Full Text] [Related]
15. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760 [TBL] [Abstract][Full Text] [Related]
16. Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Sinn BV; Weber KE; Schmitt WD; Fasching PA; Symmans WF; Blohmer JU; Karn T; Taube ET; Klauschen F; Marmé F; Schem C; Stickeler E; Ataseven B; Huober J; von Minckwitz G; Seliger B; Denkert C; Loibl S Breast Cancer Res; 2019 Dec; 21(1):142. PubMed ID: 31829264 [TBL] [Abstract][Full Text] [Related]
17. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063 [TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586 [TBL] [Abstract][Full Text] [Related]
19. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer. Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210 [TBL] [Abstract][Full Text] [Related]
20. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]